Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the FDA and the Company's plans to evaluate strategic alternatives. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the Company's planned presentation to the CHMP Scientific Advisory Group on Oncology and the effect of input of that group on the opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP, whether the timing for the final regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended June 30, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Pa. , March 3, 2015   ... laboratory products, services and solutions, announced today the ... Biolabs®, Inc. (NEB®). This agreement allows VWR increased ... technical support in the U.S. and Puerto Rico.  ... NEB,s products through VWR,s e-business platform, sales organization, ...
(Date:3/3/2015)... TUCSON, Ariz. , March 3, 2015  The ... where more than 450 of the world,s top research scientists, ... findings, discuss evolving theories and learn about new outcomes ... of medicine. Each year Ventana Medical ... Roche Group, sponsors the Tucson Symposium at the ...
(Date:3/3/2015)... and NEW YORK , March 3, ... ), a biopharmaceutical company advancing protein biologic therapies and ... at the 27 th Annual ROTH Capital Partners ... at The Ritz-Carlton, Laguna Niguel in Dana Point, California.  ... Wehner , is scheduled to present a corporate update ...
Breaking Medicine Technology:VWR Announces Expansion of Distribution Agreement with New England Biolabs 2Global scientific collaborators to explore latest pathology and oncology advancements at Tucson Symposium 2PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference 2
... DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company ... and other products focused on patients with common skin ... Officer, will present a corporate overview at the Merriman ... 2009 at 10:00 a.m. ET at the Hotel Sofitel ...
... Nov. 6 Watson Pharmaceuticals, Inc. (NYSE: WPI ... Paul Bisaro, Watson,s president and chief executive officer, will ... at the Credit Suisse 18th Annual Healthcare Conference on ... Time. , This presentation will be webcast live and ...
Cached Medicine Technology:
(Date:3/3/2015)... The Calistoga Chamber of Commerce announces a brand new event ... March 27, through Sunday, March 29, 2015. The weekend-long experience ... and bar crawl, lodging and spa specials, yoga and dining ... older. , A variety of lodging and spa properties in ... offering Mudder of All Weekends packages featuring special room rates ...
(Date:3/3/2015)... 2015 The North America ... grow from $1,224.6 million to $1,694.6 million, ... and 2019. , Browse through the TOC ... for an analysis of industry trends and ... and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , An ...
(Date:3/3/2015)... Dallas plastic surgeon , Dr. ... upcoming Dallas Rhinoplasty Symposium, to be held March 6th ... is attended by plastic surgeons and otolaryngologists from around ... information on current topics, emerging techniques, best practices, and ... , The symposium will cover a diverse array ...
(Date:3/3/2015)... March 03, 2015 Splashtop Inc. ... announces Mirroring360 is now available for Epson® MoverioTM BT-200 ... the Moverio Apps Market , iPod, iPhone, and ... experience to the Epson Moverio smart glasses using Mirroring360, ... , The Epson smart glasses have an ...
(Date:3/3/2015)... 2015 Birth Boot Camp , ... now have over 130 certified instructors in more than ... In addition, the company recently launched a new ... educator certification program . Birth Boot Camp is unique ... partner. The practical information can be used by the ...
Breaking Medicine News(10 mins):Health News:Visit Calistoga Hosts Mudder of All Weekends Girlfriend Getaway Event 2Health News:Visit Calistoga Hosts Mudder of All Weekends Girlfriend Getaway Event 3Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 3Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 2Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 3Health News:Expectant Couples Worldwide Can Now Receive Training and Education in Natural Childbirth and Breastfeeding from Birth Boot Camp 2
... of milk as a child and during adulthood ... say researchers.,Norwegian investigators have found that childhood milk ... breast cancer before the menopause.Dr Annette Hjartaker and ... premenopausal Norwegian women. Participants were asked to complete ...
... testosterone levels in men with testicular cancer may ... US researchers.,A research team from North Carolina University ... down, a high rise in levels of amyloid ... occurs. They suggest that this phenomenon might explain ...
... and non toxic method of treating Hepatitis, by administering vitaminB ... liver, and in severe cases can lead to cirrhosis, liver ... the blood or body fluids of an infected person. ... very bright and aware patient observed that his aminotransferase levels ...
... increase the risk of a gastrointestinal bleed in older ... group of antidepressants which are very widely prescribed. They ... free of side effects. But, as Researchers at Ottawa ... risk-free.// ,Almost 314,000 patients aged ...
... diehard smokers may insist that they "enjoy" their ... believe them. Since smoking involves powerful physiological and ... help only a minority succeed. Even smoking cessation ... many, have been unable to keep the majority ...
... heart disease are twice as likely to have a better ... suggests. Researchers in a Swiss study looked at patients with ... ,Doctors either gave them medication, or referred them ... with a small inflatable balloon attached is inserted and the ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: